Inclusion Criteria:

- Patients with newly histologically confirmed non-keratinizing (according to World
Health Organization (WHO 2005) histologically type).

- A Karnofsky performance status of at least 80;

- Tumor staged is according to the 7th American Joint Commission on Cancer edition as
Stage III：T1-2N2M0, T3N0-2M0 Stage IVa：T4N0-2M0 Stage IVb：Any T、N3.

- Adequate marrow: a WBC ≥3.5×109 l-1; a platelet count ≥100×109 l-1; and hemoglobin
levels ≥100 g/l.

- Normal liver function test: Alanine Aminotransferase (ALT)、Aspartate Aminotransferase
(AST) <1.5×upper limit of normal (ULN) concomitant with alkaline phosphatase (ALP)
≤2.5×ULN, and bilirubin ≤ULN.

- Adequate renal function: a creatinine clearance rate of at least 60 mL/min.

- Patients must be informed of the investigational nature of this study and give
written informed consent.

Exclusion Criteria:

- WHO Type keratinizing squamous cell carcinoma.

- Age >65 years or <18 years.

- Distant metastasis,

- Treatment with palliative intent.

- Pregnancy or lactation.

- a history of previous radiotherapy in the nasopharyngeal region or previous
chemotherapy.

- history of renal disease, unstable cardiac disease requiring treatment.